Elite Health Systems Inc. has announced that its subsidiary, Elite Health Plan, Inc., has received conditional approval from the Centers for Medicare and Medicaid Services $(CMS)$ for its Contract Year 2026 Medicare Advantage/Medicare - Prescription Drug (MA-Only/MA-PD) application. This marks a significant step for Elite Health Plan, allowing them to advance in the CMS regulatory process. However, final approval is contingent upon CMS's acceptance of Elite Health Plan's bid and formulary, as well as the completion of necessary pre-implementation activities, including system and data testing. The bid submission was conducted in partnership with Wakely Consulting Group. The process remains complex, and there is no assurance of ultimate approval or license maintenance.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。